In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $3.52.
According to TipRanks, Goldstein is a 3-star analyst with an average return of 0.7% and a 36.65% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Nektar Therapeutics.
Currently, the analyst consensus on Nektar Therapeutics is a Moderate Sell with an average price target of $5.50, which is a 56.25% upside from current levels. In a report released on November 7, SVB Securities also maintained a Hold rating on the stock with a $5.00 price target.
The company has a one-year high of $15.95 and a one-year low of $2.96. Currently, Nektar Therapeutics has an average volume of 1.63M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR: